REFERENCES
-
1 Human Genome Variation Society .Nomenclature for the description of sequence variations Web page. Available at: http://www.hgvs.org/mutnomen/ Accessed August 14, 2008
-
2
Baronciani L, Cozzi G, Canciani M T et al..
Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.
Blood Cells Mol Dis.
2003;
30
264-270
-
3
Othman M.
Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes.
Semin Thromb Hemost.
2007;
33
780-786
-
4
James P D, Notley C, Hegadorn C et al..
Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.
J Thromb Haemost.
2007;
5
1914-1922
-
5
Hilbert L, Jorieux S, Fontenay-Roupie M et al..
Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene.
Br J Haematol.
2004;
127
184-189
-
6
James P D, O'Brien L A, Hegadorn C A et al..
A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G> A) causes skipping of 2 nonadjacent exons.
Blood.
2004;
104
2739-2745
-
7
James P D, Notley C, Hegadorn C et al..
The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study.
Blood.
2007;
109
145-154
-
8
Haberichter S L, Castaman G, Budde U et al..
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Blood.
2008;
111
4979-4985
-
9
Philipp C S, Faiz A, Dowling N et al..
Age and the prevalence of bleeding disorders in women with menorrhagia.
Obstet Gynecol.
2005;
105
61-66
-
10
Lee C A, von Abdul-Kadir R.
Willebrand disease and women's health.
Semin Hematol.
2005;
42
42-48
-
11
Rodeghiero F, Kadir R A, Tosetto A, James P D.
Relevance of quantitative assessment of bleeding in haemorrhagic disorders.
Haemophilia.
2008;
14(Suppl 3)
68-75
-
12
Weiss H J.
Type 2B von Willebrand disease and related disorders of patients with increased ristocetin-induced platelet aggregation: what they tell us about the role of von Willebrand factor in hemostasis.
J Thromb Haemost.
2004;
2
2055-2056
-
13
Gnatenko D V, Perrotta P L, Bahou W F.
Proteomic approaches to dissect platelet function: half the story.
Blood.
2006;
108
3983-3991
-
14
Kandzari D E, Goldschmidt-Clermont P J.
Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors.
J Am Coll Cardiol.
2001;
38
1028-1032
-
15
Ghevaert C, Salsmann A, Watkins N A et al..
A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia.
Blood.
2008;
111
3407-3414
-
16
The British Committee for Standards in Haematology (BCSH) .
Available at: http://www.bcshguidelines.com/
Accessed August 19, 2008;
-
17
Baglin T.
Thrombophilia testing: science or medicine?.
J Clin Pathol.
2001;
54
254-255
-
18
Murphy P T.
Thrombophilia testing.
J Clin Pathol.
2000;
53
803
-
19
Asselbergs F W, Williams S M, Hebert P R et al..
Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.
Genomics.
2007;
89
362-369
Maha OthmanM.D. Ph.D.
Assistant Professor, Department of Pathology and Molecular Medicine
Queen's University, Kingston, Ontario K7L 3N6, Canada
Email: othman@queensu.ca
